These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 20443226)
1. Cyclopeptide Smac mimetics as antagonists of IAP proteins. Sun H; Liu L; Lu J; Qiu S; Yang CY; Yi H; Wang S Bioorg Med Chem Lett; 2010 May; 20(10):3043-6. PubMed ID: 20443226 [TBL] [Abstract][Full Text] [Related]
2. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells. Sun H; Lu J; Liu L; Yang CY; Wang S ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431 [TBL] [Abstract][Full Text] [Related]
3. Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. Peng Y; Sun H; Lu J; Liu L; Cai Q; Shen R; Yang CY; Yi H; Wang S J Med Chem; 2012 Jan; 55(1):106-14. PubMed ID: 22148838 [TBL] [Abstract][Full Text] [Related]
4. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. Sun H; Lu J; Liu L; Yi H; Qiu S; Yang CY; Deschamps JR; Wang S J Med Chem; 2010 Sep; 53(17):6361-7. PubMed ID: 20684551 [TBL] [Abstract][Full Text] [Related]
5. Design of small-molecule Smac mimetics as IAP antagonists. Wang S Curr Top Microbiol Immunol; 2011; 348():89-113. PubMed ID: 21072626 [TBL] [Abstract][Full Text] [Related]
6. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238 [TBL] [Abstract][Full Text] [Related]
7. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Lu J; Bai L; Sun H; Nikolovska-Coleska Z; McEachern D; Qiu S; Miller RS; Yi H; Shangary S; Sun Y; Meagher JL; Stuckey JA; Wang S Cancer Res; 2008 Nov; 68(22):9384-93. PubMed ID: 19010913 [TBL] [Abstract][Full Text] [Related]
8. Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity. Sun H; Liu L; Lu J; Bai L; Li X; Nikolovska-Coleska Z; McEachern D; Yang CY; Qiu S; Yi H; Sun D; Wang S J Med Chem; 2011 May; 54(9):3306-18. PubMed ID: 21462933 [TBL] [Abstract][Full Text] [Related]
9. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633 [TBL] [Abstract][Full Text] [Related]
10. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Nikolovska-Coleska Z; Meagher JL; Jiang S; Kawamoto SA; Gao W; Yi H; Qin D; Roller PP; Stuckey JA; Wang S Anal Biochem; 2008 Mar; 374(1):87-98. PubMed ID: 18023397 [TBL] [Abstract][Full Text] [Related]
11. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Cossu F; Mastrangelo E; Milani M; Sorrentino G; Lecis D; Delia D; Manzoni L; Seneci P; Scolastico C; Bolognesi M Biochem Biophys Res Commun; 2009 Jan; 378(2):162-7. PubMed ID: 18992220 [TBL] [Abstract][Full Text] [Related]
12. Caspase-3 deficiency reveals a physiologic role for Smac/DIABLO in regulating programmed cell death. Hui KK; Kanungo AK; Elia AJ; Henderson JT Cell Death Differ; 2011 Nov; 18(11):1780-90. PubMed ID: 21597464 [TBL] [Abstract][Full Text] [Related]
13. IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development. Ali R; Singh S; Haq W Curr Med Chem; 2018; 25(31):3768-3795. PubMed ID: 29532750 [TBL] [Abstract][Full Text] [Related]
14. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. Gao Z; Tian Y; Wang J; Yin Q; Wu H; Li YM; Jiang X J Biol Chem; 2007 Oct; 282(42):30718-27. PubMed ID: 17724022 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors. Wang J; Li W J Pharmacol Exp Ther; 2014 May; 349(2):319-29. PubMed ID: 24623800 [TBL] [Abstract][Full Text] [Related]
16. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Finlay D; Vamos M; González-López M; Ardecky RJ; Ganji SR; Yuan H; Su Y; Cooley TR; Hauser CT; Welsh K; Reed JC; Cosford ND; Vuori K Mol Cancer Ther; 2014 Jan; 13(1):5-15. PubMed ID: 24194568 [TBL] [Abstract][Full Text] [Related]
17. Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain. Donnell AF; Michoud C; Rupert KC; Han X; Aguilar D; Frank KB; Fretland AJ; Gao L; Goggin B; Hogg JH; Hong K; Janson CA; Kester RF; Kong N; Le K; Li S; Liang W; Lombardo LJ; Lou Y; Lukacs CM; Mischke S; Moliterni JA; Polonskaia A; Schutt AD; Solis DS; Specian A; Taylor RT; Weisel M; Remiszewski SW J Med Chem; 2013 Oct; 56(20):7772-87. PubMed ID: 24083782 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). Hennessy EJ; Adam A; Aquila BM; Castriotta LM; Cook D; Hattersley M; Hird AW; Huntington C; Kamhi VM; Laing NM; Li D; MacIntyre T; Omer CA; Oza V; Patterson T; Repik G; Rooney MT; Saeh JC; Sha L; Vasbinder MM; Wang H; Whitston D J Med Chem; 2013 Dec; 56(24):9897-919. PubMed ID: 24320998 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]